LNTH

Lantheus Holdings, Inc.

64.54 USD
-0.10 (-0.15%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Lantheus Holdings, Inc. stock is up 21.75% since 30 days ago. The next earnings date is May 2, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 55.56% of the previous 8 March’s closed higher than February. In the last 10 Unusual Options Trades, there were 7 CALLs, 3 PUTs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
07 Feb 16:54 19 Apr, 2024 55.00 CALL 46 227
16 Feb 14:32 19 Apr, 2024 55.00 PUT 100 400
16 Feb 20:07 15 Mar, 2024 65.00 CALL 135 141
22 Feb 14:34 15 Mar, 2024 65.00 CALL 200 369
22 Feb 16:04 19 Apr, 2024 60.00 CALL 40 341
22 Feb 18:44 18 Oct, 2024 80.00 CALL 105 0
26 Feb 16:59 15 Mar, 2024 65.00 CALL 152 542
26 Feb 20:55 17 Jan, 2025 72.50 PUT 20 3
27 Feb 17:02 18 Oct, 2024 75.00 CALL 48 43
01 Mar 16:41 18 Oct, 2024 75.00 PUT 21 0

About Lantheus Holdings, Inc.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates disease burden of prostate cancer by quantifying the hotspots on bone scans.

  • Truist Securities
    Mon Feb 26, 08:22
    buy
    confirm
  • JP Morgan
    Fri Feb 23, 12:34
    buy
    confirm